Home/Pipeline/Isoniazid Oral Solution, USP

Isoniazid Oral Solution, USP

Tuberculosis

ApprovedMarketed

Key Facts

Indication

Tuberculosis

Phase

Approved

Status

Marketed

Company

CMP Pharma

About CMP Pharma

Founded in 1975, CMP Pharma is a legacy pharmaceutical company dedicated to creating customized oral liquid and topical formulations for patients underserved by traditional solid dosage forms, particularly in acute and long-term care settings. The company has achieved significant milestones with FDA approvals for novel liquid formulations of established drugs, including Norliqva (amlodipine), Tadliq (tadalafil), and CaroSpir (spironolactone). CMP's strategy centers on identifying niche therapeutic markets, developing high-value alternative dosage forms, and manufacturing products at its facility in Farmville, North Carolina, for distribution to hospitals, long-term care facilities, and retail channels.

View full company profile

Therapeutic Areas

Cardiovascular Hypertension Pulmonary Arterial Hypertension Heart Failure Hyperkalemia Tuberculosis Dermatology Metabolic Disorders

Other Tuberculosis Drugs

Drug	Company	Phase	Status
Vaxine TB Vaccine	Vaxine	Preclinical	Active
Tuberculosis Program	Fimbrion Therapeutics	Preclinical	Active
Undisclosed Program	Crestone	Preclinical	Active
Tuberculosis Diagnostic	GenEndeavor	Research/Exploratory	Active
TB Screening LFA	DiagMetrics	Development	Active
RGFields for Tuberculosis	Anapole Technologies	Pre-clinical	Active
Tuberculosis Nanobody	VicuTec Biologicals	Pre-clinical	Active
Not specified on provided pages	Cadila Pharmaceuticals	Commercial (World's First Claim)	Marketed
TB Diagnostic & Drug Discovery	Avesthagen	Research/Discovery	Active
ALF Platform	Senzo	Pre-clinical	Active
Satiro Tablets	KYORIN Pharmaceutical	Registration	Active (In-licensed for Japan)